Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bal Pharma Limited (BALPHARMA) Stock Price & Analysis

0 Followers

BALPHARMA Stock Chart & Stats

₹82.00-₹0.20(-0.24%)
At close: 3:30 PM GMT+5:30
₹80₹90₹100₹110Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
INR 82.00 - INR 82.20
52-Week Range
INR 59.69 - INR 124.68
Previous Close
INR 82.20
Volume
N/A
Average Volume (3M)
3,583
Market Cap
INR 1.31B
Enterprise Value
INR 2.53B
Total Cash (Recent Filing)
INR 92.92M
Total Debt (Recent Filing)
INR 0
Price to Earnings (P/E)
18.1
Beta
0.59
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Sep 17, 2026
Dividend Yield
1.46%

Bulls Say, Bears Say

Bulls Say

Long-term Revenue Growth

The company has expanded revenue over the 2021–2026 period, indicating ongoing demand for its pharmaceutical products despite uneven annual performance. This provides a foundation for future operating scale, although sustaining growth will depend on improving consistency and converting sales into stronger earnings.

Diversified Pharmaceutical Model

Bal Pharma participates across finished formulations and active pharmaceutical ingredients, serving both domestic and export markets. This breadth can diversify revenue sources and reduce reliance on a single product category or geography, while supporting repeat demand from patients, distributors, and pharmaceutical customers.

Established Profitability

The company remains profitable and has generally generated positive returns on equity, showing that its manufacturing and pharmaceutical sales activities produce an economic return. Although returns are not especially strong, continued profitability can support reinvestment and help build equity over time.

Bears Say

High And Rising Leverage

High and rising leverage is a durable constraint because debt obligations can absorb a significant share of operating resources. The limited reduction in debt relative to equity leaves less flexibility to fund expansion, withstand weaker trading periods, or manage additional financing needs.

Unreliable Free Cash Flow

Repeated negative free cash flow indicates that reported profitability has not translated consistently into cash available for debt reduction or reinvestment. This weak conversion can increase reliance on borrowing and makes the company more vulnerable when working-capital needs or investment requirements rise.

Thin And Inconsistent Earnings

Thin margins and uneven earnings reduce the resilience of the business model because modest changes in product mix, pricing, or costs can materially affect profits. The 2026 earnings decline despite slightly higher revenue also suggests that growth is not yet translating reliably into improved profitability.

Bal Pharma Limited News

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?
Bal Pharma Limited lowest stock price was ₹59.69 and its highest was ₹124.68 in the past 12 months.
What is Bal Pharma Limited’s market cap?
Bal Pharma Limited’s market cap is ₹1.31B.
When is Bal Pharma Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bal Pharma Limited’s earnings last quarter?
Bal Pharma Limited released its earnings results on Aug 12, 2026. The company reported ₹0.706 earnings per share for the quarter.
Is Bal Pharma Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Bal Pharma Limited pay dividends?
Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.46%. See more information on Bal Pharma Limited dividends here
What is Bal Pharma Limited’s EPS estimate?
Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bal Pharma Limited have?
Bal Pharma Limited has 15,920,872 shares outstanding.
What happened to Bal Pharma Limited’s price movement after its last earnings report?
Bal Pharma Limited reported an EPS of ₹0.706 in its last earnings report. Following the earnings report the stock price went up 2.457%.
Which hedge fund is a major shareholder of Bal Pharma Limited?
Currently, no hedge funds are holding shares in IN:BALPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology